Sixty-three patients with lung (34 small-cell, 18 squamous, 11 adeno-) carcinomas and 43 patients with benign lung diseases were characterized with seven tumor markers: neuron-specific enolase (NSE); cancer antigens CA 19-9, CA 125, CA 15-3, and CA 50; carcinoembryonic antigen (CEA); and tissue polypeptide antigen. Diagnosis had been established by histological examination after surgery and used for classification. After vector transformation, the tumor marker data were fed into neural networks (NN5) based on three different types of learning algorithms: backpropagation (BP), competitive learning (CL), and Hopfleld (H). For comparison, the data were evaluated with multivariate stepwise discriminantanalysis (MvSDA). BP-NNs are equal to (NSE, CA 19-9, CEA) or better than (100% correct classification when using all seven markers) MVSDA in assigning the correct diagnosis to the patients. Cross-validation data yielded shrinkage effects ranging from 0% to 12.5%. Quality Various control groups were examined including 4 patients with asthma, 7 with bronchitis, 6 with bronchopneumonia, 9 with chronic obstructive lung disease, 11 with tuberculosis, and 6 with other benign lung diseases.
Neural networks use a different approach (6) (7) (8) (9) . They are based on algorithms that are capable of storing the various characteristics of different input patterns, e.g.,
combinations of laboratory results (and other information), in a system of multiple connections between socalled neurons.
These neurons are made up of mathematical formulas (input function, transfer function, output function) that summarize and process the input received from the connections attached to the neuron and deliver the result to all connections descending from it. As follows from the learning rules, the transfer functions of multilayer networks have to be nonlinear and differentiable (e.g., sigmoid, hyperbolic tangent, sine), and the input and output functions are linear (e.g., direct product, maximum). for SqCLC, 0% for LADC, and 85.7% for benign diseases for the cross-validation set.
Hopileld Network
We present no results for Hopfleld networks because we failed to obtain reasonable results with this type of network.
Competitive Learning Networks
Results for competitive learning networks evaluated with cluster analysis and backpropagation networks, are shown in 
QC Data Results
For evaluation of QC data, four backpropagation networks have been trained, with the use of four different data sets (Table 3) . Results for networks 1-3 range from 0% (set 1, rule 1) classification errors to 25.2% (set 2, rule 3) for training set vectors and from 1.9% (network 1, rule 1, set 3) to 67.7% (network 2, rule 3, set 3) for cross-validation set vectors. Network 4 is able to classify all vectors of the training set correctly; cross-validation results are between 1.3% (rule 1, set 3) and 29.4% (rule 3, set 3).
Discussion
We used two different approaches for classification of laboratory data: standard QC rulesand backpropagation networks to QC data, and MVSDA and three types of neural networks to tumor marker results.
The results for the QC data are acceptable for rules 1 and 2, but are of no practical use for rule 3. Rule 3 gives a strict cutoff value at the 2 SD limit. Such an exact yes-or-no rule is not the domain of neural networks, which deal with similnrities of various extents and are not limited to identity. Other reasons for the disappointing results for rule 3 may be the transformation method and the way the input vectors were assembled.
If vectors containing the violation of a static rule are built to present the outlying value always to the same input element, classification rates should improve. When used to check dynamic conditions such as a trend in a file of values, as in rule 1, or a shift in a target value, neural networks yield much better results.
The tumor marker data set was derived from a lung carcinoma study ( In addition, the significance of the shrinkage effect (difference between the classification rate of the training set and that of the cross-validation set) is reduced. We selected the marker combinations by MVSDA and used these combinations to construct the training files for the neural networks. We trained several networks by using the results of single markers, but the results were no better than assigning the patients by chance. This is also true for MVSDA. As an example, we presented the results obtained with NSE, which was the best single marker in this group.
The results for the three-marker combination demonstrate that more information concerning the clinical state of the patient is thereby made available, but overall classification is stifi not very good. This is in accordance with the rather low sensitivity and low specificity rates reported for tumor markers (3, 10, 16), used for diagnosticpurposes.
The results for the seven-marker network show that using more than three markers does improve the classification results of the networks, even for cross-validation sets; however, the results of MVSDA are not im- data analysis involves some difficult problems, e.g., result interpretation, and selection of input data and network structure because there is no possibility of predeterrnining which features the network is detecting. These aspects may limit their use in the medical field.
In conclusion, both methods, MVSDA and backpropagation networks, are valuable tools for assessing diagnostic information from laboratory data, especially from multiparameter data sets such as combinations of tumor marker assays. We are currently analyzing larger data sets with the same methods and the results are in strong support of those presented here. In the fields of QC data and nonsupervised learning, much more research will be necessary to establish the applicability to laboratory data analysis.
